Delivery Order SPE2DB24D3015-SPE2DB25FFZBQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,348.21 to AmerisourceBergen Drug Corp for Hydromorphone HCL ER 8 mg tablets (100-count supply) with a completion date of July 28, 2025. This contract is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location. This...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Hydromorphone HCL ER Tablets 16mg, with a contract ceiling value of $6,259.66 and a completion date of August 5, 2025. This competitive award, made without set-aside designation, is classified as a firm fixed price delivery order and represents a continuation of the federal government's ongoing pharmaceutical procurement through established...
- The Defense Logistics Agency awarded a delivery order valued at $2,127.10 to AmerisourceBergen Drug Corp for Hydromorphone 1 mg/ml, a controlled pharmaceutical used in pain management and palliative care. Issued on July 21, 2025, with an ultimate completion date of July 22, 2025, this firm fixed-price delivery order was competitively awarded without set-aside designation. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $1,144.88 to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Hydromorphone 2 mg/ml, a narcotic pain management pharmaceutical. This firm fixed-price delivery order, which is expected to be completed by August 29, 2025, carries no set-aside designation and represents a competitively awarded transaction under open competition. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $1,258.29 to AmerisourceBergen Drug Corp for the supply of Hydromorphone 0.5 mg/0.5 mL injectable solution. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 24, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a $4,722.81 delivery order to AmerisourceBergen Drug Corp for the supply of Hydromorphone 1 mg/ml on September 11, 2025, with completion targeted for September 12, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Hydromorphone 1 mg/ml with a ceiling value of $1,447.00. This firm fixed-price delivery order represents a non-competitive set-aside contract and is scheduled for completion by April 23, 2025. The award is being fulfilled from the company's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at thirty thousand dollars to Amerisourcebergen Drug Corporation for 4562094810 Hydromorphone 4 mg tablets. Under the contract, Amerisourcebergen will deliver one hundred tablets of the specified narcotic pain medication to a facility in Conshohocken, Pennsylvania by September 8, 2023. As the prime contractor, Amerisourcebergen will perform the order itself without involvement of major subcontractors. The Defense...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,711.56, is for the delivery of 4566355165 Hydromorphone HCL ER 8 mg tablets in 100-count bottles. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,383.29, is for the delivery of Hydromorphone HCL ER 8 mg tablets in quantities of 100s. The contract is a firm-fixed price delivery order, with a completion date of June 24, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FFZBQDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,197.20 to AmerisourceBergen Drug Corp for Hydromorphone HCL ER 8 mg tablets (100 count) on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency and military healthcare systems. The SPE2DX prime vendor contract enables the company to supply a comprehensive range of pharmaceutical products, medical supplies, vaccines, and specialty medications to support military healthcare programs globally. This delivery order for Hydromorphone, an opioid pain management pharmaceutical, exemplifies the company's role in fulfilling federal medical supply requirements for controlled substance medications necessary to support military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 4/24/25 |